• In late May 2026, HealthEquity, Inc. reported first-quarter revenue of US$354.64 million and net income of US$69.42 million, and raised its full-year revenue and earnings guidance while continuing its share repurchase program.
• The combination of stronger earnings, higher profit expectations for the fiscal year ending January 31, 2027, and completion of a US$244.45 million buyback adds fresh context to analysts’ prior growth and margin assumptions for the business.
• With HealthEquity lifting full-year earnings guidance, we’ll now examine how this updated outlook affects the existing investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

HealthEquity Investment Narrative Recap

To own HealthEquity, you need to believe in the long term growth of health savings accounts and the company’s ability to translate more accounts and higher balances into durable fee and interest revenue. The latest quarter’s stronger earnings and higher full year guidance support that belief without materially changing the near term catalyst, which is continued account and asset growth, or the key risk around sensitivity to interest income on custodial cash.

The most relevant update is HealthEquity’s raised outlook for the fiscal year ending January 31, 2027, now calling for US$1.410 billion to US$1.420 billion in revenue and net income of US$242 million to US$248 million. This sharper earnings view sits alongside completed buybacks and ongoing technology investment, and it frames how much cushion the company might have if interest rates, and therefore custodial yields, move against it.

Yet behind the higher guidance, one risk investors should be aware of is how quickly earnings could react if interest income on HSA cash were to...

HealthEquity's narrative projects $1.7 billion revenue and $357.1 million earnings by 2029. This requires 7.6% yearly revenue growth and a roughly $126 million earnings increase from $230.7 million today.

Uncover how HealthEquity's forecasts yield a $114.62 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value HealthEquity between US$97.01 and US$166.05, underlining how far apart individual views can be. Against this, the company’s raised earnings guidance and reliance on custodial interest income give you concrete factors to weigh as you compare these alternative perspectives.

Explore 3 other fair value estimates on HealthEquity - why the stock might be worth just $97.01!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free HealthEquity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HealthEquity's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.